1. Grosfeld, H., Velan, B., Olshevsky, U., Leitner, M., Lachmi, B.-E., Pinto, M. and Shafferman, A. 1988. An approach towards development of synthetic prototype model vaccine for alphaviruses. UCLA Symp. Mol. Cell. Biol. New Ser. 84: 87–96.
2. Grosfeld, H., Velan, B., Leitner, M., Cohen, S., Lustig, S., Lachmi, B.-E. and Shafferman, A. 1989. Semliki Forest Virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. J.Virol. 63: 3416–3422.
3. Shafferman, A., Grosfeld, H., Leitner, M., Cohen, S., Olshevsky, U., Lachmi, B.-E., Lustig, S. and Velan, B. 1990. Selection and analysis of protective epitopes on the E2 envelope of Semliki Forest Virus. In: Vaccines 90. (Eds. Brown, F., Chanock R.M., Ginsberg, H.S. and Lerner, R.A.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. p.p. 115–118
4. Grosfeld, H., Velan, B., Leitner, M., Lustig, S., Lachmi, B.-E., Cohen, S. and Shafferman, A. 1991. The delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus. Vaccine 9: 451–456.
5. Grosfeld, H., Lustig, S., Gozes, Y., Velan, B., Cohen, S., Leitner, M., Lachmi, B.-E., Katz, D., Olshevsky, U. and Shafferman, A. 1992. Divergent envelope E2 Alphavirus sequences spanning amino acids 297 to 352 induce in mice virus-specific protective immunity and antibodies with complement-mediated cy-tolytic activity. J. Virol. 66:1084–1090.